U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07351461) titled 'Anxiety in Patients Under Active Surveillance for Localized Prostate Cancer and Their Partners.' on Sept. 23, 2025.
Brief Summary: Prostate cancer (PCa) is the most common cancer and the third leading cause of cancer-related death among men in France.
Active surveillance is one of the management options for low-risk prostate cancer. Its aim is to delay or avoid radical treatment, such as surgery or radiotherapy, which can cause side effects including urinary incontinence, erectile dysfunction, or radiation-induced cystitis. Active surveillance involves regular monitoring of potential tumor progression through serum PSA testing, MRI...